Intravenous Iron Drugs Market by Product (Ferric Carboxymaltose, Iron Sucrose, Iron Dextran, and Others) and Application (Cancer, Inflammatory Bowel Disease, Chronic Kidney Disease, and Other Diseases): Global Industry Perspective, Comprehensive Analysis and Forecast, 2019 - 2025

Description

The report covers forecast and analysis for the intravenous iron drugs market on a global and regional level. The study provides historic data from 2016 along with a forecast from 2019 to 2025 based on revenue (USD Million). The study includes drivers and restraints for the intravenous iron drugs market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the intravenous iron drugs market on a global as well as regional level.

According to the report, global demand for intravenous iron drugs market was valued at approximately USD 1,699.5 Million in 2018, and is expected to generate revenue of around USD 2,851.7 Million by end of 2025, growing at a CAGR of around 7.8% between 2019 and 2025.

In order to give the users of this report a comprehensive view on the intravenous iron drugs market we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein product and services segment is benchmarked based on their market size, growth rate and general attractiveness.

The report provides company market share analysis in order to give a broader overview of the key players in the intravenous iron drugs market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the intravenous iron drugs market on global and regional basis.

Iron is one of the several minerals present inside the human body. Iron is a component of hemoglobin, which makes it an important mineral. The deficiency of iron in the body leads to inability in making hemoglobin, which may result in occurrence of anemia. The anemia arising due to low iron levels is identified as iron-deficiency anemia. Women and elderly people are at a greater risk of developing iron-deficiency anemia. Oral iron supplementation is provided to treat iron-deficiency. However, some people cannot take oral iron supplementation. People who are affected with inflammatory bowel disease, patients undergoing kidney dialysis, iron-deficiency anemia patients undergoing heavy blood loss surgery, and celiac disease patients among others are given intravenous iron drugs.

Factors such as increasing incidence of chronic renal disease, increasing geriatric population, growing number of dialysis patients, increasing cases of iron-deficiency anemia, increasing number of surgeries, and growing investment in research and development by major manufacturers will act as major driving factors in the growth of global intravenous iron drugs market. Development of novel products, growing need for prevention of anemia in pregnant women, and growing use in gynecology will act as an opportunity for the market players in the intravenous iron drugs market. Nonetheless, some side-effects associated with intravenous iron drugs, stringent regulations, high cost as compared to oral supplements, and complex approval process will restrict the growth of global intravenous iron drugs market.

The global intravenous iron drugs market has been split into product, application, and region. Based on product, intravenous iron drugs market has been segmented into ferric carboxymaltose, iron sucrose, iron dextran, and others. The ferric carboxymaltose segment accounted for the highest market share in 2018 due to growing applications of ferric carboxymaltose in drug discovery and reduction in costs. The application segment has been segmented into cancer, inflammatory bowel disease, chronic kidney disease, and other diseases. The chronic kidney disease segment accounted for the highest market share in 2018 due to growing prevalence, increasing geriatric population, and growing inclination towards sedentary lifestyle.

North America will be the leading region during the forecast period. High investment in research and development of intravenous iron drugs, applications in the field of cancer research, and growing adoption of intravenous iron drugs will boost the market growth in this region. Europe will be the second largest market. The major reasons are advantageous reimbursement scenario, high diabetes prevalence, and presence of key market players. Asia Pacific will propagate at speedy rate over the forecast period due to launch of novel products, high prevalence of chronic renal ailments, and growing investment by government in biopharmaceutical industry. Latin America market will develop at a significant rate during the forecast period. The Africa and Middle Eastern region is likely to exhibit perceptible progression in the projected time-frame.

The report also includes detailed profiles of key players such as Daiichi Sankyo Company, Ltd., Allergan, Inc., Sanofi, Rockwell Medical Technologies, Inc., Fresenius Medical Care AG & Co., AMAG Pharmaceuticals. Inc., Pharmacosmos A/S, Vifor Pharma Management Ltd., American Regent. Inc., and Shield Therapeutics Plc among others.

This report segments the Global Intravenous Iron Drugs Market as follows:

Global Intravenous Iron Drugs Market: By Product

• Ferric Carboxymaltose
• Iron Sucrose
• Iron Dextran
• Others

Global Intravenous Iron Drugs Market: By Application

• Cancer
• Inflammatory Bowel Disease
• Chronic Kidney Disease
• Other Diseases

Global Intravenous Iron Drugs Market: By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Table Of Content

• Chapter 1. Preface
  • 1.1. Report Description and Scope
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology
• Chapter 2. Executive Summary
  • 2.1. Intravenous Iron Drugs Market, 2016–2025 (USD Million)
  • 2.2. Intravenous Iron Drugs Market: Snapshot
• Chapter 3. Intravenous Iron Drugs Market – Industry Analysis
  • 3.1. Intravenous Iron Drugs Market: Market Dynamics
  • 3.2. Market Drivers
    • 3.2.1. Increasing incidence of chronic renal disease
    • 3.2.2. Increasing geriatric population
  • 3.3. Restraints
    • 3.3.1. Some side-effects associated with intravenous iron drugs
    • 3.3.2. Stringent regulations
  • 3.4. Opportunities
    • 3.4.1. Development of novel products
    • 3.4.2. Growing need for prevention of anemia in pregnant women
  • 3.5. Porter’s Five Forces Analysis
  • 3.6. Market Attractiveness Analysis
    • 3.6.1. Market attractiveness analysis By Product
    • 3.6.2. Market attractiveness analysis By Application
    • 3.6.3. Market attractiveness analysis by Region
• Chapter 4. Intravenous Iron Drugs Market– Competitive Landscape
  • 4.1. Company market share analysis
    • 4.1.1. Global Intravenous Iron Drugs Market: company market share, 2018
  • 4.2. Strategic development
    • 4.2.1. Acquisitions & mergers
    • 4.2.2. New Product launches
    • 4.2.3. Agreements, partnerships, cullaborations and joint ventures
    • 4.2.4. Research and development and Regional expansion
  • 4.3. Price trend analysis
• Chapter 5. Global Intravenous Iron Drugs Market –Product Analysis
  • 5.1. Global Intravenous Iron Drugs Market overview: By Product
    • 5.1.1. Global Intravenous Iron Drugs Market share, By Product,2018 and 2025
  • 5.2. Ferric Carboxymaltose
    • 5.2.1. Global Intravenous Iron Drugs Market by Ferric Carboxymaltose, 2016–2025 (USD Million)
  • 5.3. Iron Sucrose
    • 5.3.1. Global Intravenous Iron Drugs Market by Iron Sucrose, 2016–2025 (USD Million)
  • 5.4. Iron Dextran
    • 5.4.1. Global Intravenous Iron Drugs Market by Iron Dextran, 2016–2025 (USD Million)
  • 5.5. Others
    • 5.5.1. Global Intravenous Iron Drugs Market by Others, 2016–2025 (USD Million)
• Chapter 6. Global Intravenous Iron Drugs Market –Application Analysis
  • 6.1. Global Intravenous Iron Drugs Market overview: By Application
    • 6.1.1. Global Intravenous Iron Drugs Market share, By Application, 2018 and 2025
  • 6.2. Cancer
    • 6.2.1. Global Intravenous Iron Drugs Market By Cancer, 2016–2025 (USD Million)
  • 6.3. Inflammatory Bowel Disease
    • 6.3.1. Global Intravenous Iron Drugs Market By Inflammatory Bowel Disease, 2016–2025 (USD Million)
  • 6.4. Chronic Kidney Disease
    • 6.4.1. Global Intravenous Iron Drugs Market By Chronic Kidney Disease, 2016–2025 (USD Million)
  • 6.5. Other Diseases
    • 6.5.1. Global Intravenous Iron Drugs Market By Other Diseases, 2016–2025 (USD Million)
• Chapter 7. Global Intravenous Iron Drugs Market - Regional Analysis
  • 7.1. Global Intravenous Iron Drugs Market overview: by Region
    • 7.1.1. Global Intravenous Iron Drugs Market share, by Region, 2018 and 2025
  • 7.2. North America
    • 7.2.1. North America Intravenous Iron Drugs Market, 2016–2025 (USD Million)
    • 7.2.2. North America Intravenous Iron Drugs Market revenue, By Product,2016–2025 (USD Million)
    • 7.2.3. North America Intravenous Iron Drugs Market revenue, By Application, 2016–2025 (USD Million)
      • 7.2.4. U.S.
        • 7.2.4.1. U.S. Intravenous Iron Drugs Market revenue, By Product,2016–2025 (USD Million)
        • 7.2.4.2. U.S. Intravenous Iron Drugs Market revenue, By Application, 2016–2025 (USD Million)
    • 7.2.5. Rest of North America
      • 7.2.5.1. Rest of North America Intravenous Iron Drugs Market revenue, By Product,2016–2025 (USD Million)
      • 7.2.5.2. Rest of North America Intravenous Iron Drugs Market revenue, By Application, 2016–2025 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Intravenous Iron Drugs Market, 2016–2025 (USD Million)
    • 7.3.2. Europe Intravenous Iron Drugs Market revenue, By Product,2016–2025 (USD Million)
    • 7.3.3. Europe Intravenous Iron Drugs Market revenue, By Application, 2016–2025 (USD Million)
    • 7.3.4. UK
      • 7.3.4.1. U.K. Intravenous Iron Drugs Market revenue, By Product,2016–2025 (USD Million)
      • 7.3.4.2. U.K. Intravenous Iron Drugs Market revenue, By Application, 2016–2025 (USD Million)
    • 7.3.5. France
      • 7.3.5.1. France Intravenous Iron Drugs Market revenue, By Product,2016–2025 (USD Million)
      • 7.3.5.2. France Intravenous Iron Drugs Market revenue, By Application, 2016–2025 (USD Million)
    • 7.3.6. Germany
      • 7.3.6.1. Germany Intravenous Iron Drugs Market revenue, By Product,2016–2025 (USD Million)
      • 7.3.6.2. Germany Intravenous Iron Drugs Market revenue, By Application, 2016–2025 (USD Million)
    • 7.3.7. Rest of Europe
      • 7.3.7.1. Rest of Europe Intravenous Iron Drugs Market revenue, By Product,2016–2025 (USD Million)
      • 7.3.7.2. Rest of Europe Intravenous Iron Drugs Market revenue, By Application, 2016–2025 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Intravenous Iron Drugs Market, 2016–2025 (USD Million)
    • 7.4.2. Asia Pacific Intravenous Iron Drugs Market revenue, By Product,2016–2025 (USD Million)
    • 7.4.3. Asia Pacific Intravenous Iron Drugs Market revenue, By Application, 2016–2025 (USD Million)
    • 7.4.4. China
      • 7.4.4.1. China Intravenous Iron Drugs Market revenue, By Product,2016–2025 (USD Million)
      • 7.4.4.2. China Intravenous Iron Drugs Market revenue, By Application, 2016–2025 (USD Million)
    • 7.4.5. Japan
      • 7.4.5.1. Japan Intravenous Iron Drugs Market revenue, By Product,2016–2025 (USD Million)
      • 7.4.5.2. Japan Intravenous Iron Drugs Market revenue, By Application, 2016–2025 (USD Million)
    • 7.4.6. India
      • 7.4.6.1. India Intravenous Iron Drugs Market revenue, By Product,2016–2025 (USD Million)
      • 7.4.6.2. India Intravenous Iron Drugs Market revenue, By Application, 2016–2025 (USD Million)
    • 7.4.7. Rest of Asia Pacific
      • 7.4.7.1. Rest of Asia Pacific Intravenous Iron Drugs Market revenue, By Product,2016–2025 (USD Million)
      • 7.4.7.2. Rest of Asia Pacific Intravenous Iron Drugs Market revenue, By Application, 2016–2025 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Intravenous Iron Drugs Market, 2016–2025 (USD Million)
    • 7.5.2. Latin America Intravenous Iron Drugs Market revenue, By Product,2016–2025 (USD Million)
    • 7.5.3. Latin America Intravenous Iron Drugs Market revenue, By Application, 2016–2025 (USD Million)
    • 7.5.4. Brazil
      • 7.5.4.1. Brazil Intravenous Iron Drugs Market revenue, By Product,2016–2025 (USD Million)
      • 7.5.4.2. Brazil Intravenous Iron Drugs Market revenue, By Application, 2016–2025 (USD Million)
    • 7.5.5. Rest of Latin America
      • 7.5.5.1. Rest of Latin America Intravenous Iron Drugs Market revenue, By Product,2016–2025 (USD Million)
      • 7.5.5.2. Rest of Latin America Intravenous Iron Drugs Market revenue, By Application, 2016–2025 (USD Million)
  • 7.6. The Middle East and Africa
    • 7.6.1. The Middle East and Africa Intravenous Iron Drugs Market, 2016–2025 (USD Million)
    • 7.6.2. The Middle East and Africa Intravenous Iron Drugs Market revenue, By Product,2016–2025 (USD Million)
    • 7.6.3. The Middle East and Africa Intravenous Iron Drugs Market revenue, By Application, 2016–2025 (USD Million)
• Chapter 8. Company Profiles
  • 8.1. Daiichi Sankyo Company, Ltd.
    • 8.1.1. Overview
    • 8.1.2. Financials
    • 8.1.3. Product Portfolio
    • 8.1.4. Business Strategy
    • 8.1.5. Recent Developments
  • 8.2. Allergan, Inc.
    • 8.2.1. Overview
    • 8.2.2. Financials
    • 8.2.3. Product Portfolio
    • 8.2.4. Business Strategy
    • 8.2.5. Recent Developments
  • 8.3. Sanofi
    • 8.3.1. Overview
    • 8.3.2. Financials
    • 8.3.3. Product Portfolio
    • 8.3.4. Business Strategy
    • 8.3.5. Recent Developments
  • 8.4. Rockwell Medical Technologies, Inc.
    • 8.4.1. Overview
    • 8.4.2. Financials
    • 8.4.3. Product Portfolio
    • 8.4.4. Business Strategy
    • 8.4.5. Recent Developments
  • 8.5. Fresenius Medical Care AG & Co.
    • 8.5.1. Overview
    • 8.5.2. Financials
    • 8.5.3. Product Portfolio
    • 8.5.4. Business Strategy
    • 8.5.5. Recent Development
  • 8.6. AMAG Pharmaceuticals. Inc.
    • 8.6.1. Overview
    • 8.6.2. Financials
    • 8.6.3. Product Portfolio
    • 8.6.4. Business Strategy
    • 8.6.5. Recent Development
  • 8.7. Pharmacosmos A/S
    • 8.7.1. Overview
    • 8.7.2. Financials
    • 8.7.3. Product Portfolio
    • 8.7.4. Business Strategy
    • 8.7.5. Recent Development
  • 8.8. Vifor Pharma Management Ltd.
    • 8.8.1. Overview
    • 8.8.2. Financials
    • 8.8.3. Product Portfolio
    • 8.8.4. Business Strategy
    • 8.8.5. Recent Development
  • 8.9. American Regent. Inc.
    • 8.9.1. Overview
    • 8.9.2. Financials
    • 8.9.3. Product Portfolio
    • 8.9.4. Business Strategy
    • 8.9.5. Recent Development
  • 8.10. Shield Therapeutics Plc
    • 8.10.1. Overview
    • 8.10.2. Financials
    • 8.10.3. Product Portfolio
    • 8.10.4. Business Strategy
    • 8.10.5. Recent Development

Methodology